1. 453PD1st-line mFOLFOXIRI + panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: A randomized phase II VOLFI trial of the AIO (KRK-0109). (23rd October 2018) Authors: Geissler, M; Klingler, T; Riera Knorrenschild, J; Tannapfel, A; Greeve, J; Seufferlein, T; Kanzler, S; Held, S; Heinemann, V; Reinacher-Schick, A; Martens, U M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗